Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Appoints-Sravan-K.-Emany-as-Chief-Financial-Officer/default.aspx
Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Reports-Third-Quarter-2021-Results-and-Provides-Corporate-Development-Update/default.aspx
Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Expands-Pipeline-by-Signing-an-Option-Agreement-to-Acquire-an-Exclusive-License-with-COUR-Pharmaceuticals-to-Develop-and-Commercialize-CNP-104-for-the-Treatment-of-Primary-Biliary-Cholangitis-PBC-in-the-U.S/default.aspx
Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Reports-Third-Quarter-2021-Results-and-Provides-Corporate-Development-Update/default.aspx
Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Expands-Pipeline-by-Signing-an-Option-Agreement-to-Acquire-an-Exclusive-License-with-COUR-Pharmaceuticals-to-Develop-and-Commercialize-CNP-104-for-the-Treatment-of-Primary-Biliary-Cholangitis-PBC-in-the-U.S/default.aspx
More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/More-than-90-of-Surveyed-IBS-C-Patients-Who-Had-an-ER-Visit-or-Hospitalization-in-the-Past-Year-Identified-Abdominal-Pain-as-a-Symptom-That-Led-to-the-Visit-According-to-Data-Announced-by-Ironwood-Pharmaceuticals-at-ACG-2021/default.aspx
More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/More-than-90-of-Surveyed-IBS-C-Patients-Who-Had-an-ER-Visit-or-Hospitalization-in-the-Past-Year-Identified-Abdominal-Pain-as-a-Symptom-That-Led-to-the-Visit-According-to-Data-Announced-by-Ironwood-Pharmaceuticals-at-ACG-2021/default.aspx
Ironwood Pharmaceuticals to Host Third Quarter 2021 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2021-Investor-Update-Call/default.aspx
Ironwood Pharmaceuticals to Host Third Quarter 2021 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2021-Investor-Update-Call/default.aspx
Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-to-Participate-in-Upcoming-September-Investor-Conferences/default.aspx